1. Market Research
  2. > Pharmaceutical Market Trends

Pharmaceutical Industry in Ghana and Nigeria

  • June 2014
  • 204 pages
  • Frost & Sullivan
Report ID: 445046


Table of Contents

A Ripe Business Opportunity for Big Pharma and Generic Pharma Companies

The pharmaceutical industry in Ghana and Nigeria is forecast to represent a combined business opportunity of over $3 billion by 2018, propelled by a convergence of changing economic profiles, increased healthcare spending and investment, and increasing incidence of chronic diseases. Market segmentation is done based on products (OTC, generic, and branded) as well as therapeutic areas (anti-infectives, cardiovascular, diabetes, oncology, respiratory, and CNS). This study provides a detailed analysis that includes market overview, market engineering measurements, revenue forecasts, competitive analysis, and key trends for the pharmaceutical industry in Ghana and Nigeria.


-Primary interviews were conducted with industry stakeholders such as Tier I and Tier II pharmaceutical companies, industry experts, and regulatory authorities. Designation of interviewed participants include chief executive officers, marketing managers, directors, and vice presidents.
-Secondary research sources such as in-house Frost & Sullivan database, Frost & Sullivan’s Decision Support Database, company annual reports, scientific journals, and industry-related articles have been utilised.
-For the purpose of this research, West African pharmaceutical industry refers to the pharmaceutical industry in Ghana and Nigeria.
-Revenues include drug sales from local manufacturers, multinational companies that either establish their own business units or trade via a local distributor as well as imports from generic pharmaceutical companies.
-Over-the-counter (OTC) products have been included in the scope of this study.

Key Findings

-In 2013, the pharmaceutical industry of Ghana and Nigeria was valued at $ billion. It is expected to witness a compound annual growth rate (CAGR) of % and generate a revenue of $ billion in 2018.
-Nigeria accounted for % of the revenue in the total Ghanaian and Nigerian pharmaceutical industry in 2013 because of its large size, while Ghana accounted for the remaining %.
-In 2013, the generic pharmaceutical segment represented the highest revenue share of %, while the branded pharmaceutical segment represented the least.
-The OTC pharmaceutical segment is considerably large in Ghana and Nigeria, constituting % of the total pharmaceutical industry, attributable to the large number of local manufacturers particularly in the anti-infectives, analgesics, and multivitamins product segments.
-In 2013, the anti-infectives therapeutic segment accounted for the highest revenue share of% of the total pharmaceutical industry in Ghana and Nigeria. It is expected to witness a high CAGR from 2013 to 2018 and remain the largest therapeutic segment during the forecast period.
-Although the oncology therapeutic segment accounted for the smallest revenue share in 2013, it is expected to be the fastest growing segment during the forecast period, given the increasing awareness about cancer in Ghana and Nigeria.
-The cardiovascular and diabetes therapeutic segments are also projected to witness high growth rates during the forecast period as a result of increasing adoption of western lifestyle, driving the demand for consumption of chronic drugs.
-The continuous burden of anti-infectives, including malaria, tuberculosis (TB), and HIV/AIDS in West Africa is expected to be the major growth driver for this industry.
-The increased prevalence of non-communicable diseases (NCDs) such as hypertension, diabetes, and cancer in Ghana and Nigeria is expected to have a high impact on the growth of the total pharmaceutical industry as the demand for chronic prescription therapy for these diseases rises.
-The recent achievement of % NHIS coverage in Ghana in 2013 is expected to result in high growth of the pharmaceutical industry, particularly the prescription pharmaceutical (generic and branded) segment, because of easy accessibility and affordability of medicines.
-The judicious efforts of the Food and Drugs Board (FDB) (Ghana) and National Agency for Food (NAFDAC) (Nigeria) to control parallel trading and imports of counterfeit drugs are expected to contribute to the growth of the legitimate pharmaceutical industry in Ghana and Nigeria.
-Furthermore, the governments are also encouraging the local production of essential medicines to improve capacity utilisation and reduce imports.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:


The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

PharmaFocus: Tauopathies - Global Market Analysis

  • $ 9495
  • Industry report
  • February 2017
  • by GlobalData

PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...

Pharmaceutical Hot Melt Extrusion Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • February 2017
  • by Transparency Market Research

Global Pharmaceutical Hot Melt Extrusion Market: Overview This report provides forecast and analysis of the pharmaceutical hot melt extrusion market on the global and regional levels. It provides historical ...

Pulmonary/ Respiratory Drug Delivery Market by Formulation, Device Type, Canister, End User, Applications - Forecasts to 2021

  • $ 5650
  • Industry report
  • February 2017
  • by MarketsandMarkets

The global pulmonary drug delivery market is projected to reach USD 52.37 billion by 2021 from USD 36.10 billion in 2016, at a CAGR of 6.5% during the forecast period. Increasing preference of pulmonary ...


Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.